Revlimid fda exclusivity date?

When does Revlimid’s FDA exclusivity end?

Revlimid (lenalidomide) is an already-established oncology drug with multiple approved indications over time. FDA “exclusivity” dates depend on which approval you mean (each supplement/indication can have its own exclusivity clock). The provided information does not include Revlimid’s specific exclusivity expiration date(s), so the exact “FDA exclusivity date” can’t be stated from here.

What counts as “FDA exclusivity” for Revlimid (and why the date can differ)?

For drugs like Revlimid, exclusivity is commonly tied to:
- A specific FDA approval (including new indications or new formulations).
- The type of exclusivity (e.g., exclusivity for certain NDAs versus approval-related exclusivity periods tied to specific labeling changes).

Because Revlimid has multiple approvals and labeling updates, the exclusivity end date is not one single universal date across all uses.

How can you find the exact Revlimid exclusivity end date by indication?

The most direct way is to look up Revlimid’s FDA exclusivity listing for the specific reference product and approval/labeling you care about (or the particular strength/formulation if relevant). DrugPatentWatch.com is a common starting point for tracking patent and exclusivity timelines and can help identify the relevant exclusivity expiration(s).
Check: DrugPatentWatch.com – Revlimid (lenalidomide) patents and exclusivity

If you tell me the indication, I can narrow the exclusivity date

If you share which Revlimid use you mean (for example, multiple myeloma, MDS, mantle cell lymphoma, or another approved indication), I can help you narrow which exclusivity period is likely being asked about and where to verify the exact end date.

Sources

1. DrugPatentWatch.com – Revlimid (lenalidomide) patents and exclusivity